AR882 + febuxostat

AR882 + febuxostat is a combination therapy under investigation for the treatment of gout and hyperuricemia. AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which blocks the reabsorption of uric acid in the renal tubules, thereby increasing urinary excretion and lowering serum urate levels[3][7][8]. Febuxostat is a non-purine, selective xanthine oxidase/dehydrogenase inhibitor that reduces serum uric acid by inhibiting its synthesis[2][6]. The combination aims to provide additive or synergistic effects on lowering serum urate, with clinical studies showing greater reductions in serum urate compared to either agent alone[3]. This approach may benefit patients with severe or refractory gout who do not achieve target serum urate levels with monotherapy.

Brand names

Uloric (for febuxostat)